2016 Q2 Form 10-Q Financial Statement

#000156459016022692 Filed on August 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $891.0K $306.0K
YoY Change 191.18% 209.09%
Cost Of Revenue $168.0K $0.00
YoY Change
Gross Profit $723.0K $306.0K
YoY Change 136.27%
Gross Profit Margin 81.14% 100.0%
Selling, General & Admin $5.056M $4.622M
YoY Change 9.39% 25.09%
% of Gross Profit 699.31% 1510.46%
Research & Development $4.444M $4.142M
YoY Change 7.29% 47.19%
% of Gross Profit 614.66% 1353.59%
Depreciation & Amortization $251.0K $135.0K
YoY Change 85.93% 40.63%
% of Gross Profit 34.72% 44.12%
Operating Expenses $9.500M $8.764M
YoY Change 8.4% 34.64%
Operating Profit -$8.777M -$8.458M
YoY Change 3.77% 31.95%
Interest Expense $30.00K $3.000K
YoY Change 900.0%
% of Operating Profit
Other Income/Expense, Net $32.00K -$33.00K
YoY Change -196.97% 43.48%
Pretax Income -$8.750M -$8.490M
YoY Change 3.06% 32.04%
Income Tax $22.00K $3.000K
% Of Pretax Income
Net Earnings -$8.767M -$8.491M
YoY Change 3.25% 31.99%
Net Earnings / Revenue -983.95% -2774.84%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.898M -$1.887M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.54M $86.00M
YoY Change -37.74% 91.54%
Cash & Equivalents $53.54M $86.00M
Short-Term Investments
Other Short-Term Assets $1.030M $800.0K
YoY Change 28.75% 12.68%
Inventory $510.0K $70.00K
Prepaid Expenses
Receivables $100.0K $130.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $55.18M $87.00M
YoY Change -36.57% 90.21%
LONG-TERM ASSETS
Property, Plant & Equipment $3.460M $3.380M
YoY Change 2.37% 237.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $210.0K $190.0K
YoY Change 10.53% 115.91%
Total Long-Term Assets $3.670M $3.560M
YoY Change 3.09% 204.79%
TOTAL ASSETS
Total Short-Term Assets $55.18M $87.00M
Total Long-Term Assets $3.670M $3.560M
Total Assets $58.85M $90.56M
YoY Change -35.02% 93.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $480.0K $1.030M
YoY Change -53.4% 22.77%
Accrued Expenses $1.860M $2.730M
YoY Change -31.87% 56.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $30.00K
YoY Change -100.0%
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.140M $5.230M
YoY Change -39.96% 69.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $870.0K $20.00K
YoY Change 4250.0%
Total Long-Term Liabilities $870.0K $20.00K
YoY Change 4250.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.140M $5.230M
Total Long-Term Liabilities $870.0K $20.00K
Total Liabilities $4.000M $5.240M
YoY Change -23.66% 69.58%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $54.84M $85.32M
YoY Change
Total Liabilities & Shareholders Equity $58.85M $90.56M
YoY Change -35.02% 93.06%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$8.767M -$8.491M
YoY Change 3.25% 31.99%
Depreciation, Depletion And Amortization $251.0K $135.0K
YoY Change 85.93% 40.63%
Cash From Operating Activities -$8.540M -$6.300M
YoY Change 35.56% -285.29%
INVESTING ACTIVITIES
Capital Expenditures $12.00K $1.135M
YoY Change -98.94% 376.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$1.140M
YoY Change -99.12% 375.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $46.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 43.29M
YoY Change -100.0% 13018.18%
NET CHANGE
Cash From Operating Activities -8.540M -6.300M
Cash From Investing Activities -10.00K -1.140M
Cash From Financing Activities 0.000 43.29M
Net Change In Cash -8.550M 35.85M
YoY Change -123.85% 954.41%
FREE CASH FLOW
Cash From Operating Activities -$8.540M -$6.300M
Capital Expenditures $12.00K $1.135M
Free Cash Flow -$8.552M -$7.435M
YoY Change 15.02% -335.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5056000
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4622000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4444000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-8767000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
54843000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58847000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92389730
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92389730
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
674000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92391964
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82993966
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
251000
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135000
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5000
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
38000
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1429000
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1780000
CY2016Q2 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0
CY2015Q2 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
-95000
CY2016Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-156000
CY2015Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
132000
CY2016Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
178000
CY2015Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3000
CY2016Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
41000
CY2015Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-256000
CY2016Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-306000
CY2015Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-357000
CY2016Q2 onvo Revenue From Research Collaborations
RevenueFromResearchCollaborations
213000
CY2016Q2 us-gaap Revenue From Grants
RevenueFromGrants
4000
CY2015Q2 us-gaap Revenue From Grants
RevenueFromGrants
83000
CY2016Q2 us-gaap Revenues
Revenues
891000
CY2015Q2 us-gaap Revenues
Revenues
306000
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
168000
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
0
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4142000
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
9668000
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
8764000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8777000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8458000
CY2016Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-5000
CY2015Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-38000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-8491000
CY2016Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-735000
CY2015Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-611000
CY2016Q2 onvo Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-36000
CY2015Q2 onvo Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-8000
CY2016Q2 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-319000
CY2015Q2 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1193000
CY2016Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8541000
CY2015Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6295000
CY2016Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
CY2015Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1135000
CY2016Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12000
CY2015Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1135000
CY2016Q2 onvo Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0
CY2015Q2 onvo Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
43214000
CY2016Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2015Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
77000
CY2016Q2 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
0
CY2015Q2 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
3000
CY2016Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0
CY2015Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
43288000
CY2016Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8553000
CY2015Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
35858000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50142000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86000000
CY2016Q2 us-gaap Interest Paid
InterestPaid
0
CY2015Q2 us-gaap Interest Paid
InterestPaid
0
CY2016Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
22000
CY2015Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
3000
CY2015Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
138000
CY2015Q2 onvo Leasehold Improvements Funded By Lease Incentive
LeaseholdImprovementsFundedByLeaseIncentive
337000
CY2016Q2 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in computing the valuation of warrants, revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. </p></div>
CY2016Q2 us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue arrangements with multiple deliverables </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows ASC 605-25 <font style="font-style:italic;">Revenue Recognition &#8211; Multiple-Element Arrangements</font> for revenue arrangements that contain multiple deliverables. Judgment is required to properly identify the accounting units of the multiple deliverable transactions and to determine the manner in which revenue should be allocated among the accounting units. Moreover, judgment is used in interpreting the commercial terms and determining when all criteria of revenue recognition have been met for each deliverable in order for revenue recognition to occur in the appropriate accounting period. For multiple deliverable agreements, consideration is allocated at the inception of the agreement to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (&#8220;VSOE&#8221;) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While changes in the allocation of the arrangement consideration between the units of accounting will not affect the amount of total revenue recognized for a particular sales arrangement, any material changes in these allocations could impact the timing of revenue recognition, which could affect the Company&#8217;s results of operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically receives license fees for non-exclusive research licensing associated with funded research projects. License fees under these arrangements are recognized over the term of the contract or development period as it has been determined that such licenses do not have stand-alone value. </p></div>
CY2016Q2 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product revenue </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes product revenue at the time of shipment to the customer, provided all other revenue recognition criteria have been met. To date, the Company has not recognized significant revenue from commercial product sales.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our commercial sales increase, we expect to establish a reserve for estimated product returns that will be recorded as a reduction to revenue. This reserve will be maintained to account for future return of products sold in the current period. The reserve will be reviewed quarterly and will be estimated based on an analysis of our historical experience related to product returns.</p></div>
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5862904
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.79
CY2016Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2015Q2 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11600000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10200000
CY2011 onvo Class Of Warrant Or Right Life
ClassOfWarrantOrRightLife
P5Y
CY2012 onvo Class Of Warrant Or Right Life
ClassOfWarrantOrRightLife
P5Y
CY2016Q2 onvo Number Of Warrant Exercised During Period Recorded As Derivative Liability
NumberOfWarrantExercisedDuringPeriodRecordedAsDerivativeLiability
0
CY2015Q2 onvo Number Of Warrant Exercised During Period Recorded As Derivative Liability
NumberOfWarrantExercisedDuringPeriodRecordedAsDerivativeLiability
38234
CY2016Q2 onvo Stockholders Equity During Period Issuance Of Common Stock From Warrant Exercises
StockholdersEquityDuringPeriodIssuanceOfCommonStockFromWarrantExercises
0
CY2015Q2 onvo Stockholders Equity During Period Issuance Of Common Stock From Warrant Exercises
StockholdersEquityDuringPeriodIssuanceOfCommonStockFromWarrantExercises
30186
CY2016Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0
CY2015Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
38234
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
25503
CY2016Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2015Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25503
CY2016Q2 onvo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Upon Return Of Common Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUponReturnOfCommonShares
2259
CY2015Q2 onvo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Upon Return Of Common Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUponReturnOfCommonShares
2259
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9614627
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
416640
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
22970
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10008297
CY2016Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.21
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.64
CY2016Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.72
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.55
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1927137
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7092419
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5416930
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M5D
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M5D
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7130
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7425
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.03
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.22
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11840000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
145000
CY2014Q4 onvo Class Of Warrant Or Right Life
ClassOfWarrantOrRightLife
P5Y
CY2014Q4 onvo Warrant Earning Period Through Issuance Of Common Stock
WarrantEarningPeriodThroughIssuanceOfCommonStock
P17M
CY2016Q2 onvo Number Of Warrant Shares Vested Upon Satisfaction Of Specific Performance Metrics
NumberOfWarrantSharesVestedUponSatisfactionOfSpecificPerformanceMetrics
95000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0120
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.734
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0121
CY2016Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17150435
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 onvo Number Of Non Cancelable Leases
NumberOfNonCancelableLeases
3
CY2016Q2 onvo Operating Leases Monthly Rent Expense
OperatingLeasesMonthlyRentExpense
83000
CY2016Q2 us-gaap Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate
OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate
0.03
CY2016Q2 onvo Office Space Area Under Lease Agreement
OfficeSpaceAreaUnderLeaseAgreement
30895
CY2016Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-09-01
CY2016Q2 onvo Lease Option Termination Description
LeaseOptionTerminationDescription
option to terminate on or after September 1, 2019
CY2016Q2 onvo Additional Office Space
AdditionalOfficeSpace
14500
CY2015Q1 onvo Additional Leased Office Space
AdditionalLeasedOfficeSpace
5803
CY2015Q1 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P36M
CY2015Q1 onvo Lease Rental Period Start Date
LeaseRentalPeriodStartDate
2015-02-01
CY2015Q1 onvo Lease Rental Period End Date
LeaseRentalPeriodEndDate
2018-01-31
CY2015Q1 onvo Operating Leases Monthly Base Rent Expense
OperatingLeasesMonthlyBaseRentExpense
12000
CY2015Q1 us-gaap Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate
OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate
0.03
CY2015Q4 onvo Additional Leased Office Space
AdditionalLeasedOfficeSpace
12088
CY2015Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P12M
CY2015Q4 onvo Lease Rental Period Start Date
LeaseRentalPeriodStartDate
2016-02-01
CY2015Q4 onvo Lease Rental Period End Date
LeaseRentalPeriodEndDate
2017-01-31
CY2015Q4 onvo Operating Leases Monthly Base Rent Expense
OperatingLeasesMonthlyBaseRentExpense
15000
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
303000
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
277000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
976000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1148000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1044000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1072000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1104000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
468000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5812000

Files In Submission

Name View Source Status
0001564590-16-022692-index-headers.html Edgar Link pending
0001564590-16-022692-index.html Edgar Link pending
0001564590-16-022692.txt Edgar Link pending
0001564590-16-022692-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
onvo-10q_20160630.htm Edgar Link pending
onvo-20160630.xml Edgar Link completed
onvo-20160630.xsd Edgar Link pending
onvo-20160630_cal.xml Edgar Link unprocessable
onvo-20160630_def.xml Edgar Link unprocessable
onvo-20160630_lab.xml Edgar Link unprocessable
onvo-20160630_pre.xml Edgar Link unprocessable
onvo-ex101_237.htm Edgar Link pending
onvo-ex102_236.htm Edgar Link pending
onvo-ex103_238.htm Edgar Link pending
onvo-ex104_235.htm Edgar Link pending
onvo-ex311_234.htm Edgar Link pending
onvo-ex321_232.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending